Connect with us

Hi, what are you looking for?

Jewish Business News

StartUps

Carl Berg, Real Estate Mogul, Is Looking To Make The Treatment Of Chronic Illnesses More Efficient

Berg has devoted considerable time, energy as well as capital in his latest venture, Berg Pharma in the search for  new treatments for life-threatening diseases.

Carl Berg Courtesy of Mission West Properties

Carl Berg, who built up a billion dollar real estate empire in California’s  Silicon Valley is nurturing his latest project, Berg Pharma which he established in 2007 to find modern treatments for some of the world’s most widespread diseases.

In order to find these treatments Berg Pharma uses a number of the most modern facets of  communications technology, such as  data analytics and processing as well as artificial intelligence in order to research cures  for  life threatening diseases such as   cancer and stage two diabetes that have become increasingly prevalent in recent years.

Berg, who sold his real estate business in 2012 for $1.2 billion has not been taking life any easier, despite the fact that he is now well into his seventies.  Instead, Berg Pharma  is focusing on  developing  technology that will not only arrest the spread of “modern day maladies”   in half the time that conventional medicine has been taking, with improved results and  at considerably reduced costs.

The thinking behind Berg Pharma’s new approach  is to look upon  pharmaceutical research as a “Big Data” problem,  which can be overcome through the utilization of artificial intelligence that will allow the company’s  team of medical researchers to better understand the underlying biology behind diseases such as  cancer and diabetes, Berg Pharma have a mission to  rapidly develop treatments that will arrest the spread of these chronic diseases  as well as put an end to  the devastating effects that they bring on the people who suffer from these diseases.

Berg Pharma’s Interrogative Biology discovery platform has been developed to  develop  computer simulation of the proteins, lipids and metabolites found  in both healthy and diseased cells. When these cells have been isolated, then the discovery platform will be capable of referring to algorithms, that are capable of identifying specific patterns in thye cells and how they healthy and diseased cells differ. Once the identification process has been completed, then the research team at Berg Pharma can begin to identify the specific proteins which can be utilized to return the diseased cell  to a more normal mode.

Berg’s approach appears to be bringing results, with four treatments developed by the company advancing well through their  clinical trials, with cautious optimism that the  first treatment should be ready for release  within the next two to three  years.

Berg Pharma’s research is certainly beginning to capture the imagination of the pharmaceutical industry, with them being the recipients of the prestigious  Frost & Sullivan award for innovation in drug discovery, while  the company has now formed partnerships with  a number of the most important medical schools and hospitals in the United States, including the Icahn School of Medicine at Mount Sinai, the University of Texas MD Anderson Cancer Center, and the US  Department of Defense.

What makes Berg Pharmastand out from the traditional pharmaceutical companies, according to Carl Berg, is that it is based around a business model driven by computer analytics meaning that its research costs are lower. That means that the research department can be considerably less labor intensive, translated to the fact that the  company currently has a payroll of   300, a mere  fraction of what a traditional  pharmaceutical company would normally employ to carry out a similar scale of research.

According to Carl Berg, his company’s success  will be based not only on the strengths of their first class research team, and the most advanced  technology that they have at their fingertips, but also to the long term business structure that  Berg has put in place since he formed the company seven years ago.

And with a personal fortune estimated to be well over one billion dollars, Berg can afford to wait in the sincere belief that his philosophy will help to improve the life of millions.

 

Carl Berg graduated from the University of New Mexico in the late nineteen fifties and went on to build a real estate empire, the bulk of which he sold  to property development giant  Divco West in late 2012 for the sum of  $1.3 billion. Currently, Berg, apart from his interest in Berg Pharma, holds considerable  investments in Berg & Berg Enterprises, LLC , International Network Services and Valence Technologies.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

empty

The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Advertisement
cialis cialis satış